Tevogen (TVGN) Amortizatization of Intangibles (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Amortizatization of Intangibles came in at $28783.0 in Q1 2026, down 55.62% YoY from $64849.0 in Q1 2025, and up 3.82% on a QoQ basis from $27725.0 in Q4 2025.
Tevogen (TVGN) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Amortizatization of Intangibles data on file, last reported at $28783.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 55.62% year-over-year to $28783.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $282558.0 (up 13.72% YoY) and the FY2025 annual result came in at $318624.0, up 32.01% from the prior year.
- Amortizatization of Intangibles rose to $28783.0 in Q1 2026, from $27725.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $199343.0 in Q2 2025 to a low of $26707.0 in Q3 2025.
- A 4-year average of $61833.5 and a median of $56775.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 235.38% in 2025, down 56.35% in 2025.
- Tracing TVGN's Amortizatization of Intangibles over 4 years: stood at $56775.0 in 2023, then gained by 10.96% to $62995.0 in 2024, then plunged by 55.99% to $27725.0 in 2025, then gained by 3.82% to $28783.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $28783.0 (Q1 2026), $27725.0 (Q4 2025), and $26707.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28,783.00 |
| Mar 31, 2026 | 28,783.00 |
| Dec 31, 2025 | 27,725.00 |
| Dec 31, 2025 | 27,725.00 |
| Sep 30, 2025 | 26,707.00 |
| Sep 30, 2025 | 26,707.00 |
| Jun 30, 2025 | 199,343.00 |
| Jun 30, 2025 | 199,343.00 |
| Mar 31, 2025 | 64,849.00 |
| Mar 31, 2025 | 64,849.00 |
| Dec 31, 2024 | 62,995.00 |
| Dec 31, 2024 | 62,995.00 |
| Sep 30, 2024 | 61,188.00 |
| Sep 30, 2024 | 61,188.00 |
| Jun 30, 2024 | 59,438.00 |
| Jun 30, 2024 | 59,438.00 |
| Mar 31, 2024 | 57,751.00 |
| Mar 31, 2024 | 57,751.00 |
| Dec 31, 2023 | 56,775.00 |
| Dec 31, 2023 | 56,775.00 |